Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 310

1.

Final results of a randomized multicenter phase II study of alvocidib, cytarabine, and mitoxantrone versus cytarabine and daunorubicin (7 + 3) in newly diagnosed high-risk acute myeloid leukemia (AML).

Zeidner JF, Foster MC, Blackford AL, Litzow MR, Morris LE, Strickland SA, Lancet JE, Bose P, Levy MY, Tibes R, Gojo I, Gocke CD, Rosner GL, Little RF, Wright JJ, Doyle LA, Smith BD, Karp JE.

Leuk Res. 2018 Aug 10;72:92-95. doi: 10.1016/j.leukres.2018.08.005. [Epub ahead of print] No abstract available.

PMID:
30118897
2.

Sorafenib Dose Recommendation in Acute Myeloid Leukemia Based on Exposure-FLT3 Relationship.

Liu T, Ivaturi V, Sabato P, Gobburu JVS, Greer JM, Wright JJ, Smith BD, Pratz KW, Rudek MA; ETCTN-6745 study team.

Clin Transl Sci. 2018 Jul;11(4):435-443. doi: 10.1111/cts.12555. Epub 2018 Apr 27.

3.

Molecular Pharmacodynamics-Guided Scheduling of Biologically Effective Doses: A Drug Development Paradigm Applied to MET Tyrosine Kinase Inhibitors.

Srivastava AK, Hollingshead MG, Govindharajulu JP, Covey JM, Liston D, Simpson MA, Peggins JO, Bottaro DP, Wright JJ, Kinders RJ, Doroshow JH, Parchment RE.

Mol Cancer Ther. 2018 Mar;17(3):698-709. doi: 10.1158/1535-7163.MCT-17-0552. Epub 2018 Feb 14.

PMID:
29444985
4.

Diverse Marinimicrobia bacteria may mediate coupled biogeochemical cycles along eco-thermodynamic gradients.

Hawley AK, Nobu MK, Wright JJ, Durno WE, Morgan-Lang C, Sage B, Schwientek P, Swan BK, Rinke C, Torres-Beltrán M, Mewis K, Liu WT, Stepanauskas R, Woyke T, Hallam SJ.

Nat Commun. 2017 Nov 15;8(1):1507. doi: 10.1038/s41467-017-01376-9.

5.

Using Hyperfine Electron Paramagnetic Resonance Spectroscopy to Define the Proton-Coupled Electron Transfer Reaction at Fe-S Cluster N2 in Respiratory Complex I.

Le Breton N, Wright JJ, Jones AJY, Salvadori E, Bridges HR, Hirst J, Roessler MM.

J Am Chem Soc. 2017 Nov 15;139(45):16319-16326. doi: 10.1021/jacs.7b09261. Epub 2017 Nov 3.

PMID:
29039928
6.

Phase I study of sorafenib and tipifarnib for recurrent glioblastoma: NABTC 05-02.

Nghiemphu PL, Ebiana VA, Wen P, Gilbert M, Abrey LE, Lieberman F, DeAngelis LM, Robins HI, Yung WKA, Chang S, Drappatz J, Mehta MP, Levin VA, Aldape K, Dancey JE, Wright JJ, Prados M, Kuhn J, Cloughesy TF.

J Neurooncol. 2018 Jan;136(1):79-86. doi: 10.1007/s11060-017-2624-4. Epub 2017 Oct 7.

PMID:
28988377
7.

Genetic variation and biogeography of the spotted gar Lepisosteus oculatus from core and peripheral populations.

David SR, Wright JJ.

J Exp Zool B Mol Dev Evol. 2017 Nov;328(7):596-606. doi: 10.1002/jez.b.22772. Epub 2017 Oct 5.

PMID:
28980772
8.

A new diminutive genus and species of catfish from Lake Tanganyika (Siluriformes: Clariidae).

Wright JJ.

J Fish Biol. 2017 Sep;91(3):789-805. doi: 10.1111/jfb.13374. Epub 2017 Jul 26.

PMID:
28744868
9.

Randomized phase II trial of fulvestrant alone or in combination with bortezomib in hormone receptor-positive metastatic breast cancer resistant to aromatase inhibitors: a New York Cancer Consortium trial.

Adelson K, Ramaswamy B, Sparano JA, Christos PJ, Wright JJ, Raptis G, Han G, Villalona-Calero M, Ma CX, Hershman D, Baar J, Klein P, Cigler T, Budd GT, Novik Y, Tan AR, Tannenbaum S, Goel A, Levine E, Shapiro CL, Andreopoulou E, Naughton M, Kalinsky K, Waxman S, Germain D.

NPJ Breast Cancer. 2016 Dec 14;2:16037. doi: 10.1038/npjbcancer.2016.37. eCollection 2016.

10.

Retuning the Catalytic Bias and Overpotential of a [NiFe]-Hydrogenase via a Single Amino Acid Exchange at the Electron Entry/Exit Site.

Adamson H, Robinson M, Wright JJ, Flanagan LA, Walton J, Elton D, Gavaghan DJ, Bond AM, Roessler MM, Parkin A.

J Am Chem Soc. 2017 Aug 9;139(31):10677-10686. doi: 10.1021/jacs.7b03611. Epub 2017 Jul 26.

11.

A Phase Ib Study of Sorafenib (BAY 43-9006) in Patients with Kaposi Sarcoma.

Uldrick TS, Gonçalves PH, Wyvill KM, Peer CJ, Bernstein W, Aleman K, Polizzotto MN, Venzon D, Steinberg SM, Marshall V, Whitby D, Little RF, Wright JJ, Rudek MA, Figg WD, Yarchoan R.

Oncologist. 2017 May;22(5):505-e49. doi: 10.1634/theoncologist.2016-0486. Epub 2017 Mar 24.

12.

Exposure-Response Analysis of Alvocidib (Flavopiridol) Treatment by Bolus or Hybrid Administration in Newly Diagnosed or Relapsed/Refractory Acute Leukemia Patients.

LaCerte C, Ivaturi V, Gobburu J, Greer JM, Doyle LA, Wright JJ, Karp JE, Rudek MA.

Clin Cancer Res. 2017 Jul 15;23(14):3592-3600. doi: 10.1158/1078-0432.CCR-16-2629. Epub 2017 Feb 7.

13.

Further Work on the Shaping of Cortical Development and Function by Synchrony and Metabolic Competition.

Wright JJ, Bourke PD.

Front Comput Neurosci. 2016 Dec 9;10:127. doi: 10.3389/fncom.2016.00127. eCollection 2016.

14.

Ammonium and nitrite oxidation at nanomolar oxygen concentrations in oxygen minimum zone waters.

Bristow LA, Dalsgaard T, Tiano L, Mills DB, Bertagnolli AD, Wright JJ, Hallam SJ, Ulloa O, Canfield DE, Revsbech NP, Thamdrup B.

Proc Natl Acad Sci U S A. 2016 Sep 20;113(38):10601-6. doi: 10.1073/pnas.1600359113. Epub 2016 Sep 6.

15.

Self-reported Barriers to Adherence and Persistence to Treatment With Injectable Medications for Type 2 Diabetes.

Spain CV, Wright JJ, Hahn RM, Wivel A, Martin AA.

Clin Ther. 2016 Jul;38(7):1653-1664.e1. doi: 10.1016/j.clinthera.2016.05.009. Epub 2016 Jun 28.

16.

Pharmacologic Therapy of Type 2 Diabetes.

Wright JJ, Tylee TS.

Med Clin North Am. 2016 Jul;100(4):647-63. doi: 10.1016/j.mcna.2016.03.014. Review.

PMID:
27235609
17.

Small-volume potentiometric titrations: EPR investigations of Fe-S cluster N2 in mitochondrial complex I.

Wright JJ, Salvadori E, Bridges HR, Hirst J, Roessler MM.

J Inorg Biochem. 2016 Sep;162:201-206. doi: 10.1016/j.jinorgbio.2016.04.025. Epub 2016 Apr 20.

18.

Re-engineering a NiFe hydrogenase to increase the H2 production bias while maintaining native levels of O2 tolerance.

Flanagan LA, Wright JJ, Roessler MM, Moir JW, Parkin A.

Chem Commun (Camb). 2016 Jul 12;52(58):9133-6. doi: 10.1039/c6cc00515b.

19.

A Novel Itc Approach: Matching Patient-Level Data To Study-Level Summary Means And Variances.

Alsop JC, Regnier SA, Wright JJ.

Value Health. 2015 Nov;18(7):A687. doi: 10.1016/j.jval.2015.09.2543. Epub 2015 Oct 20. No abstract available.

20.

Phase II study of tivantinib (ARQ 197) in patients with metastatic triple-negative breast cancer.

Tolaney SM, Tan S, Guo H, Barry W, Van Allen E, Wagle N, Brock J, Larrabee K, Paweletz C, Ivanova E, Janne P, Overmoyer B, Wright JJ, Shapiro GI, Winer EP, Krop IE.

Invest New Drugs. 2015 Oct;33(5):1108-14. doi: 10.1007/s10637-015-0269-8. Epub 2015 Jul 1.

21.

Randomized multicenter phase II study of flavopiridol (alvocidib), cytarabine, and mitoxantrone (FLAM) versus cytarabine/daunorubicin (7+3) in newly diagnosed acute myeloid leukemia.

Zeidner JF, Foster MC, Blackford AL, Litzow MR, Morris LE, Strickland SA, Lancet JE, Bose P, Levy MY, Tibes R, Gojo I, Gocke CD, Rosner GL, Little RF, Wright JJ, Doyle LA, Smith BD, Karp JE.

Haematologica. 2015 Sep;100(9):1172-9. doi: 10.3324/haematol.2015.125849. Epub 2015 May 28.

22.

Catholics, science and civic culture in Victorian Belfast.

Finnegan DA, Wright JJ.

Br J Hist Sci. 2015 Jun;48(2):261-87. doi: 10.1017/S0007087414000594.

PMID:
25921682
23.

A Phase II Study of Sorafenib Combined With Cetuximab in EGFR-Expressing, KRAS-Mutated Metastatic Colorectal Cancer.

Do K, Cao L, Kang Z, Turkbey B, Lindenberg ML, Larkins E, Holkova B, Steinberg SM, Raffeld M, Peer CJ, Figg WD, Eugeni M, Jacobs P, Choyke P, Wright JJ, Doroshow JH, Kummar S.

Clin Colorectal Cancer. 2015 Sep;14(3):154-61. doi: 10.1016/j.clcc.2015.02.007. Epub 2015 Mar 7.

PMID:
25861837
24.

Female sexual dysfunction.

Wright JJ, O'Connor KM.

Med Clin North Am. 2015 May;99(3):607-28. doi: 10.1016/j.mcna.2015.01.011. Epub 2015 Mar 6. Review.

PMID:
25841603
25.

A phase i study of DMS612, a novel bifunctional alkylating agent.

Appleman LJ, Balasubramaniam S, Parise RA, Bryla C, Redon CE, Nakamura AJ, Bonner WM, Wright JJ, Piekarz R, Kohler DR, Jiang Y, Belani CP, Eiseman J, Chu E, Beumer JH, Bates SE.

Clin Cancer Res. 2015 Feb 15;21(4):721-9. doi: 10.1158/1078-0432.CCR-14-1333. Epub 2014 Dec 2.

26.

Möbius-strip-like columnar functional connections are revealed in somato-sensory receptive field centroids.

Wright JJ, Bourke PD, Favorov OV.

Front Neuroanat. 2014 Oct 31;8:119. doi: 10.3389/fnana.2014.00119. eCollection 2014.

27.

Sorafenib dose escalation is not uniformly associated with blood pressure elevations in normotensive patients with advanced malignancies.

Karovic S, Wen Y, Karrison TG, Bakris GL, Levine MR, House LK, Wu K, Thomeas V, Rudek MA, Wright JJ, Cohen EE, Fleming GF, Ratain MJ, Maitland ML.

Clin Pharmacol Ther. 2014 Jul;96(1):27-35. doi: 10.1038/clpt.2014.63. Epub 2014 Mar 17.

28.

Randomized phase II trial of sorafenib alone or in combination with carboplatin/paclitaxel in women with recurrent platinum sensitive epithelial ovarian, peritoneal, or fallopian tube cancer.

Schwandt A, von Gruenigen VE, Wenham RM, Frasure H, Eaton S, Fusco N, Fu P, Wright JJ, Dowlati A, Waggoner S.

Invest New Drugs. 2014 Aug;32(4):729-38. doi: 10.1007/s10637-014-0078-5. Epub 2014 Mar 12.

PMID:
24619298
29.

Hypotheses about the psychological benefits of horses.

Kendall E, Maujean A, Pepping CA, Wright JJ.

Explore (NY). 2014 Mar-Apr;10(2):81-7. doi: 10.1016/j.explore.2013.12.001. Epub 2013 Dec 17.

PMID:
24607074
30.

Phase II trial of bortezomib alone or in combination with irinotecan in patients with adenocarcinoma of the gastroesophageal junction or stomach.

Ocean AJ, Christos P, Sparano JA, Shah MA, Yantiss RK, Cheng J, Lin J, Papetti M, Matulich D, Schnoll-Sussman F, Besanceney-Webler C, Xiang J, Ward M, Dilts KT, Keresztes R, Holloway S, Chen EX, Wright JJ, Lane ME.

Invest New Drugs. 2014 Jun;32(3):542-8. doi: 10.1007/s10637-014-0070-0. Epub 2014 Feb 15.

31.

A phase II trial of the proteasome inhibitor bortezomib in patients with advanced biliary tract cancers.

Denlinger CS, Meropol NJ, Li T, Lewis NL, Engstrom PF, Weiner LM, Cheng JD, Alpaugh RK, Cooper H, Wright JJ, Cohen SJ.

Clin Colorectal Cancer. 2014 Jun;13(2):81-6. doi: 10.1016/j.clcc.2013.12.005. Epub 2014 Jan 4.

32.

Phase 2 randomized, flexible crossover, double-blinded, placebo-controlled trial of the farnesyltransferase inhibitor tipifarnib in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromas.

Widemann BC, Dombi E, Gillespie A, Wolters PL, Belasco J, Goldman S, Korf BR, Solomon J, Martin S, Salzer W, Fox E, Patronas N, Kieran MW, Perentesis JP, Reddy A, Wright JJ, Kim A, Steinberg SM, Balis FM.

Neuro Oncol. 2014 May;16(5):707-18. doi: 10.1093/neuonc/nou004. Epub 2014 Feb 4.

33.

Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor Consortium trial 04-02.

Wen PY, Chang SM, Lamborn KR, Kuhn JG, Norden AD, Cloughesy TF, Robins HI, Lieberman FS, Gilbert MR, Mehta MP, Drappatz J, Groves MD, Santagata S, Ligon AH, Yung WK, Wright JJ, Dancey J, Aldape KD, Prados MD, Ligon KL.

Neuro Oncol. 2014 Apr;16(4):567-78. doi: 10.1093/neuonc/not247. Epub 2014 Jan 26.

34.

A phase II trial of saracatinib, an inhibitor of src kinases, in previously-treated advanced non-small-cell lung cancer: the princess margaret hospital phase II consortium.

Laurie SA, Goss GD, Shepherd FA, Reaume MN, Nicholas G, Philip L, Wang L, Schwock J, Hirsh V, Oza A, Tsao MS, Wright JJ, Leighl NB.

Clin Lung Cancer. 2014 Jan;15(1):52-7. doi: 10.1016/j.cllc.2013.08.001. Epub 2013 Oct 26.

PMID:
24169259
35.

A phase I study of vorinostat in combination with bortezomib in patients with advanced malignancies.

Schelman WR, Traynor AM, Holen KD, Kolesar JM, Attia S, Hoang T, Eickhoff J, Jiang Z, Alberti D, Marnocha R, Reid JM, Ames MM, McGovern RM, Espinoza-Delgado I, Wright JJ, Wilding G, Bailey HH.

Invest New Drugs. 2013 Dec;31(6):1539-46. doi: 10.1007/s10637-013-0029-6. Epub 2013 Oct 10.

36.

Phase II study of dasatinib (BMS-354825) in patients with metastatic adenocarcinoma of the pancreas.

Chee CE, Krishnamurthi S, Nock CJ, Meropol NJ, Gibbons J, Fu P, Bokar J, Teston L, O'Brien T, Gudena V, Reese A, Bergman M, Saltzman J, Wright JJ, Dowlati A, Brell J.

Oncologist. 2013;18(10):1091-2. doi: 10.1634/theoncologist.2013-0255. Epub 2013 Sep 26.

37.

Phase I-II study of the farnesyl transferase inhibitor tipifarnib plus sequential weekly paclitaxel and doxorubicin-cyclophosphamide in HER2/neu-negative inflammatory carcinoma and non-inflammatory estrogen receptor-positive breast carcinoma.

Andreopoulou E, Vigoda IS, Valero V, Hershman DL, Raptis G, Vahdat LT, Han HS, Wright JJ, Pellegrino CM, Cristofanilli M, Alvarez RH, Fehn K, Fineberg S, Sparano JA.

Breast Cancer Res Treat. 2013 Oct;141(3):429-35. doi: 10.1007/s10549-013-2704-x. Epub 2013 Sep 26.

38.

Genomic properties of Marine Group A bacteria indicate a role in the marine sulfur cycle.

Wright JJ, Mewis K, Hanson NW, Konwar KM, Maas KR, Hallam SJ.

ISME J. 2014 Feb;8(2):455-68. doi: 10.1038/ismej.2013.152. Epub 2013 Sep 12.

39.

Vorinostat in combination with bortezomib in patients with advanced malignancies directly alters transcription of target genes.

Kolesar JM, Traynor AM, Holen KD, Hoang T, Seo S, Kim K, Alberti D, Espinoza-Delgado I, Wright JJ, Wilding G, Bailey HH, Schelman WR.

Cancer Chemother Pharmacol. 2013 Sep;72(3):661-7. doi: 10.1007/s00280-013-2242-6. Epub 2013 Aug 1.

40.

Prevalent genome streamlining and latitudinal divergence of planktonic bacteria in the surface ocean.

Swan BK, Tupper B, Sczyrba A, Lauro FM, Martinez-Garcia M, González JM, Luo H, Wright JJ, Landry ZC, Hanson NW, Thompson BP, Poulton NJ, Schwientek P, Acinas SG, Giovannoni SJ, Moran MA, Hallam SJ, Cavicchioli R, Woyke T, Stepanauskas R.

Proc Natl Acad Sci U S A. 2013 Jul 9;110(28):11463-8. doi: 10.1073/pnas.1304246110. Epub 2013 Jun 25.

41.

On the dynamics of cortical development: synchrony and synaptic self-organization.

Wright JJ, Bourke PD.

Front Comput Neurosci. 2013 Feb 15;7:4. doi: 10.3389/fncom.2013.00004. eCollection 2013.

42.

A multi-histology trial of fostamatinib in patients with advanced colorectal, non-small cell lung, head and neck, thyroid, and renal cell carcinomas, and pheochromocytomas.

Park SR, Speranza G, Piekarz R, Wright JJ, Kinders RJ, Wang L, Pfister T, Trepel JB, Lee MJ, Alarcon S, Steinberg SM, Collins J, Doroshow JH, Kummar S.

Cancer Chemother Pharmacol. 2013 Apr;71(4):981-90. doi: 10.1007/s00280-013-2091-3. Epub 2013 Feb 13.

43.

1-(4-Phenylpiperazin-1-yl)-2-(1H-pyrazol-1-yl)ethanones as novel CCR1 antagonists.

Pennell AM, Aggen JB, Sen S, Chen W, Xu Y, Sullivan E, Li L, Greenman K, Charvat T, Hansen D, Dairaghi DJ, Wright JJ, Zhang P.

Bioorg Med Chem Lett. 2013 Mar 1;23(5):1228-31. doi: 10.1016/j.bmcl.2013.01.005. Epub 2013 Jan 11.

PMID:
23374868
44.

Mechanisms and spatial context: comment on "Dissipation of 'dark energy' by cortex in knowledge retrieval" by Antonio Capolupo, Walter J. Freeman and Giuseppe Vitiello.

Wright JJ.

Phys Life Rev. 2013 Mar;10(1):99-100; discussion 112-6. doi: 10.1016/j.plrev.2013.01.002. Epub 2013 Jan 11. No abstract available.

PMID:
23333570
45.

Information provision for stroke patients and their caregivers.

Forster A, Brown L, Smith J, House A, Knapp P, Wright JJ, Young J.

Cochrane Database Syst Rev. 2012 Nov 14;11:CD001919. doi: 10.1002/14651858.CD001919.pub3. Review.

PMID:
23152210
46.

Diversity and population structure of Marine Group A bacteria in the Northeast subarctic Pacific Ocean.

Allers E, Wright JJ, Konwar KM, Howes CG, Beneze E, Hallam SJ, Sullivan MB.

ISME J. 2013 Feb;7(2):256-68. doi: 10.1038/ismej.2012.108. Epub 2012 Nov 15.

47.

Phase II trial of sorafenib in patients with advanced anaplastic carcinoma of the thyroid.

Savvides P, Nagaiah G, Lavertu P, Fu P, Wright JJ, Chapman R, Wasman J, Dowlati A, Remick SC.

Thyroid. 2013 May;23(5):600-4. doi: 10.1089/thy.2012.0103. Epub 2013 Apr 18.

48.

Phase I/II study of sorafenib in combination with temsirolimus for recurrent glioblastoma or gliosarcoma: North American Brain Tumor Consortium study 05-02.

Lee EQ, Kuhn J, Lamborn KR, Abrey L, DeAngelis LM, Lieberman F, Robins HI, Chang SM, Yung WK, Drappatz J, Mehta MP, Levin VA, Aldape K, Dancey JE, Wright JJ, Prados MD, Cloughesy TF, Gilbert MR, Wen PY.

Neuro Oncol. 2012 Dec;14(12):1511-8. doi: 10.1093/neuonc/nos264. Epub 2012 Oct 24.

49.

Design and implementation of a genomics field trip program aimed at secondary school students.

McQueen J, Wright JJ, Fox JA.

PLoS Comput Biol. 2012;8(8):e1002636. doi: 10.1371/journal.pcbi.1002636. Epub 2012 Aug 30.

50.

Phase II trial of the histone deacetylase inhibitor romidepsin in patients with recurrent/metastatic head and neck cancer.

Haigentz M Jr, Kim M, Sarta C, Lin J, Keresztes RS, Culliney B, Gaba AG, Smith RV, Shapiro GI, Chirieac LR, Mariadason JM, Belbin TJ, Greally JM, Wright JJ, Haddad RI.

Oral Oncol. 2012 Dec;48(12):1281-8. doi: 10.1016/j.oraloncology.2012.05.024. Epub 2012 Jun 28.

Supplemental Content

Loading ...
Support Center